Previous 10 | Next 10 |
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...
2023-12-12 13:17:41 ET More on Johnson & Johnson Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Stocks To Watch: Big Week On Tap For McDonald's, Shopify, GameStop, And Johnson & Johnson Johnson & Johnson: Sleep Well At Night With The Only AAA-Rate...
2023-12-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-11 06:20:03 ET AbbVie ( NYSE: ABBV ) and Genmab ( GMAB ) on Saturday presented latest trial data for their lymphoma drug candidate epcoritamab in patients with difficult-to-treat relapsed/refractory (R/R) follicular lymphoma (FL). Updated data from Phase 1/2 EPCO...
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) PR Newswire - Data from Phase 1/2 EPCORE™ NHL-1 study show patients tre...
Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcori...
2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares ( HBANL ) +3% . Genmab ( GMAB ) +3% . Losers: Fluence En...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
2023-11-27 08:03:06 ET More on AbbVie, Genmab, etc. AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation AbbVie suing Sandoz, four others to block ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...